Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose intestinal irradiation plus PD-1 inhibitor in immunotherapy-resistant advanced NSCLC
ChiCTR2500107664Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Started Jul 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500107664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107664.